Caracal has opened a recycling facility in Baltimore dedicated to medical plastics, marking the company's entry into a hospital waste stream that most processors still refuse on paper — and, in practice, in person.

The facility, announced by the company and reported by PlasticsToday, will handle plastics collected from healthcare settings, where rigid packaging, instruments and device housings typically leave the building as regulated waste rather than as commodity feedstock.

What does the plant actually take in?

Medical recycling sits apart from standard municipal or industrial streams. Hospitals generate large volumes of clean, high-value polymers — sterile packaging, non-contaminated rigid plastics — but collection, segregation and compliance costs have kept most of that material out of the recycling system.

Caracal's Baltimore operation is built to address that gap: a dedicated site, in a major healthcare corridor, designed to process material that conventional material recovery facilities will not accept. The company has not yet published tonnage targets or throughput figures for the plant. Until it does, the facility is best read as built capacity with an unannounced ceiling.

That distinction matters. Announced projects are plentiful in this sector; operating lines are fewer. Baltimore now hosts one of them.

Why medical plastics, and why now?

The healthcare sector's plastics problem is structural. Single-use devices and packaging have multiplied over two decades, while recycling infrastructure for the resulting material has barely moved. Processors who can guarantee chain-of-custody handling and produce consistent, contaminant-free flake or pellet are scarce.

A dedicated facility answers two objections at once. It separates medical material from general streams, easing regulatory concern. And it concentrates volumes in one place, which is what buyers of recycled resin demand before they will commit to offtake.

Caracal is positioning itself as that concentrator. The Baltimore site gives the company a physical anchor in a market where logistics — not chemistry — is usually the binding constraint.

What to watch next

The credible milestones from here are concrete. First, published throughput: a tonnage figure for the Baltimore plant would convert an opening into a measurable operation. Second, offtake agreements: resin buyers signing contracts would signal that the output meets specification. Third, hospital supply contracts upstream, which determine whether the plant runs full or hungry.

Each of those checkpoints is falsifiable, which is more than can be said for most circularity pledges in this corner of the industry.

For now, the plant stands open. The tonnage ledger is blank, and the market will fill it.

By Olivia Hart, Circular Wire